Achilles Therapeutics Targets The Root Of Cancer

02 Nov 2016

• By Lubna Ahmed

Emerging Company Profile: With funding from Cancer Research UK and Syncona – and a wealth of science from its founders – newly launched London-based immuno-oncology company Achilles Therapeutics, believes it has identified cancer's weak spot.

Achilles' ultimate aim, according to CEO Chris Ashton, is to improve the current standard of care for those suffering with cancer by "cutting off the trunk of the cancer tree" and targeting what he believes to be the Achilles’ heel of the disease; the truncal initial mutations said to be present in every cancer cell.

The premise behind the company is based on research, recently published in Science,that details a way in which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

11 Jun 2025

• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

21 May 2025

• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

09 Jun 2025

• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.